Serum PARC/CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease

D.D. Sin, B.E. Miller, A. Duvoix, S.F. Man, X. Zhang, E.K. Silverman, J.E. Connett, N.A. Anthonisen, R.A. Wise, D. Tashkin, B.R. Celli, L.D. Edwards, N. Locantore, W. MacNee, R. Tal-Singer, (incl. E. Wouters) ECLIPSE Investigators, D.A. Lomas

Research output: Contribution to journalArticleAcademicpeer-review


RATIONALE: There are no accepted blood-based biomarkers in chronic obstructive pulmonary disease (COPD). Pulmonary and activation-regulated chemokine (PARC/CCL-18) is a lung-predominant inflammatory protein that is found in serum. OBJECTIVES: To determine whether PARC/CCL-18 levels are elevated and modifiable in COPD and to determine their relationship to clinical end points of hospitalization and mortality. Methods: PARC/CCL-18 was measured in serum samples from individuals who participated in the ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints) and LHS (Lung Health Study) studies and a prednisolone intervention study. MEASUREMENTS AND MAIN RESULTS: Serum PARC/CCL-18 levels were higher in subjects with COPD than in smokers or lifetime nonsmokers without COPD (105 vs. 81 vs. 80 ng/ml, respectively; P < 0.0001). Elevated PARC/CCL-18 levels were associated with increased risk of cardiovascular hospitalization or mortality in the LHS cohort and with total mortality in the ECLIPSE cohort. CONCLUSIONS: Serum PARC/CCL-18 levels are elevated in COPD and track clinical outcomes. PARC/CCL-18, a lung-predominant chemokine, could be a useful blood biomarker in COPD.
Original languageEnglish
Pages (from-to)1187-1192
Number of pages6
JournalAmerican Journal of Respiratory and Critical Care Medicine
Issue number9
Publication statusPublished - 1 May 2011


  • biomarker
  • chronic obstructive pulmonary disease
  • PARC/CCL-18
  • chemokine
  • COPD
  • CCL18

Cite this